Avelumab

mCRC

ImmunityBio, Inc.monoclonal_antibodyPhase 1/2Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 30/ 100
Competitive Position: 81/ 100

Competitive context

12 Active assets in the mCRC cohort.

Asset / Sponsor	Phase	Rating
Calcium folinate pentahydrate Shanghai Henlius Biotech	Phase 2	B
FLUOROURACILUM Shanghai Henlius Biotech	Phase 2	B
Eloxatin Shanghai Henlius Biotech	Phase 2	B
Tuvonralimab Huazhong University of Science and Technology	Phase 2	CCC
Pelareorep Oncolytics Biotech	Phase 2	CCC

View all 20 →

Same molecule, other indications

Avelumab is also rated in:

non-small cell lung carcinomaDormant

B

Indicative ·

58 / 100

urothelial carcinomaDormant

B

Indicative ·

58 / 100

bladder transitional cell carcinomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.